T790M mutation in stage IV EGFR-mutated NSCLC patient with acquired resistance reverted to original 19Del mutation after administration of a series of precision treatments: a case report

Abstract Existing studies have yet to elucidate clearly the mechanisms of secondary resistance to third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), neither is there any established standard therapy for patients resistant to third generation EGFR-TKIs. This c...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Precision clinical medicine 2018-12, Vol.1 (3), p.129-133
Hauptverfasser:	Han, Jialong, Wang, Ya, Zhong, Lili, Zhou, Huijie, Yu, Min, Li, Yanying, Lu, You, Wang, Yan, Zhu, Jiang
Format:	Artikel
Sprache:	eng
Schlagworte:	Case Report
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!